Orexigen Therapeutics, Inc. (OREX) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q1 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $857 thousand versus the consensus estimate of $900 thousand.
For earnings history and earnings-related data on Orexigen Therapeutics, Inc. (OREX) click here.
For earnings history and earnings-related data on Orexigen Therapeutics, Inc. (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Bloom Energy stock rises on analyst support and AI outlook
- Seagate Technology stock rises ahead of earnings report
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
